MX2023002468A - Sales, cristales y cocristales novedosos. - Google Patents

Sales, cristales y cocristales novedosos.

Info

Publication number
MX2023002468A
MX2023002468A MX2023002468A MX2023002468A MX2023002468A MX 2023002468 A MX2023002468 A MX 2023002468A MX 2023002468 A MX2023002468 A MX 2023002468A MX 2023002468 A MX2023002468 A MX 2023002468A MX 2023002468 A MX2023002468 A MX 2023002468A
Authority
MX
Mexico
Prior art keywords
sub
crystals
novel salts
receptor
sert
Prior art date
Application number
MX2023002468A
Other languages
English (en)
Spanish (es)
Inventor
Peng Li
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of MX2023002468A publication Critical patent/MX2023002468A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00—Purification; Separation; Stabilisation; Use of additives
    • C07B63/02—Purification; Separation; Stabilisation; Use of additives by treatment giving rise to a chemical modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
MX2023002468A 2020-09-04 2021-09-03 Sales, cristales y cocristales novedosos. MX2023002468A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063075019P 2020-09-04 2020-09-04
PCT/US2021/071366 WO2022051770A2 (en) 2020-09-04 2021-09-03 Novel salts, crystals, and co-crystals

Publications (1)

Publication Number Publication Date
MX2023002468A true MX2023002468A (es) 2023-03-23

Family

ID=80492079

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002468A MX2023002468A (es) 2020-09-04 2021-09-03 Sales, cristales y cocristales novedosos.

Country Status (10)

Country Link
US (1) US20230312573A1 (cg-RX-API-DMAC7.html)
EP (1) EP4208434A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023540506A (cg-RX-API-DMAC7.html)
KR (1) KR20230104121A (cg-RX-API-DMAC7.html)
CN (1) CN116113622A (cg-RX-API-DMAC7.html)
AU (1) AU2021338439A1 (cg-RX-API-DMAC7.html)
CA (1) CA3186537A1 (cg-RX-API-DMAC7.html)
IL (1) IL300886A (cg-RX-API-DMAC7.html)
MX (1) MX2023002468A (cg-RX-API-DMAC7.html)
WO (1) WO2022051770A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3600325A4 (en) 2017-03-24 2021-01-06 Intra-Cellular Therapies, Inc. UNIQUE COMPOSITIONS AND PROCESSES
WO2019178484A1 (en) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
SMT202600133T1 (it) 2018-03-23 2026-05-12 Intra Cellular Therapies Inc Composti organici
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
US20250352469A1 (en) 2024-05-16 2025-11-20 Intra-Cellular Therapies, Inc. Novel compositions, devices, and methods
CN118566395B (zh) * 2024-08-02 2024-10-25 则正(济南)生物科技有限公司 测定甲苯磺酸卢美哌隆口崩片中杂质含量的方法、应用和系统

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL281050B2 (en) * 2016-03-25 2023-04-01 Intra Cellular Therapies Inc A controlled or delayed release pharmaceutical preparation containing a deuterated compound
WO2017172811A1 (en) * 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel co-crystals
EP3600325A4 (en) * 2017-03-24 2021-01-06 Intra-Cellular Therapies, Inc. UNIQUE COMPOSITIONS AND PROCESSES
WO2018189646A1 (en) * 2017-04-10 2018-10-18 Dr. Reddy's Laboratories Limited AMORPHOUS FORM AND SOLID DISPERSIONS OF LUMATEPERONE p-TOSYLATE
WO2019067591A1 (en) * 2017-09-26 2019-04-04 Intra-Cellular Therapies, Inc. NEW SALTS AND CRYSTALS
BR112020024885A2 (pt) * 2018-06-06 2021-03-09 Intra-Cellular Therapies, Inc. Novos sais e cristais
RS67906B1 (sr) * 2018-06-11 2026-04-30 Intra Cellular Therapies Inc Sinteza supstituisanih heterociklično fuzionisanih gama-karbolina
US12144808B2 (en) * 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
WO2020112941A2 (en) * 2018-11-27 2020-06-04 Teva Czech Industries S.R.O Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof
EP4134101A1 (en) * 2019-07-07 2023-02-15 Intra-Cellular Therapies, Inc. Deuterated lumateperone for the treatment of the bipolar ii disorder
JP2022549335A (ja) * 2019-09-25 2022-11-24 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規方法

Also Published As

Publication number Publication date
WO2022051770A3 (en) 2022-04-14
EP4208434A4 (en) 2024-10-16
JP2023540506A (ja) 2023-09-25
US20230312573A1 (en) 2023-10-05
CN116113622A (zh) 2023-05-12
AU2021338439A1 (en) 2023-02-23
EP4208434A2 (en) 2023-07-12
CA3186537A1 (en) 2022-03-10
IL300886A (en) 2023-04-01
WO2022051770A2 (en) 2022-03-10
KR20230104121A (ko) 2023-07-07
JP2026117004A (ja) 2026-07-14

Similar Documents

Publication Publication Date Title
WO2022051770A3 (en) Novel salts, crystals, and co-crystals
MX2020000967A (es) Compuestos organicos.
Kiss et al. Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3/D2 dopamine receptor antagonist–partial agonist antipsychotic candidate: in vitro and neurochemical profile
JP2019513143A5 (cg-RX-API-DMAC7.html)
MX2022007105A (es) Formas solidas de sal de 1,3-dihidroxi-2-(hidroximetil)propan-2-am ina de acido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1, 3] dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il) metil)-1h- benzo[d]imidazol-6-carboxilico.
BR112019019928A2 (pt) derivados de indolina substituídos como inibidores da replicação viral da dengue
JP2019513140A5 (cg-RX-API-DMAC7.html)
JP2014525470A5 (cg-RX-API-DMAC7.html)
RU2006135652A (ru) Производные индол-1-илуксусной кислоты
EA201891267A1 (ru) Фармацевтическая композиция, содержащая действенный ингибитор urat1
UY28578A1 (es) Derivados de amida
NO20074781L (no) 4-Oksokinazolin-3-ylbenzamidderivater for behandling av cytokinsykdommer
BR112019020175A2 (pt) Derivados de indolina substituídos como inibidores da replicação viral da dengue
BR112016022785B1 (pt) Composto inibidor de triptofano-2,3-dioxigenase (tdo) e/ou indoleamina-2,3-dioxigenase (ido), composição farmacêutica, e, uso de composto inibidor de triptofano-2,3-dioxigenase (tdo) e/ou indoleamina-2,3dioxigenase (ido) ou de um sal farmaceuticamente aceitável do mesmo para fabricação de um medicamento
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
UA125296C2 (uk) Заміщені похідні індоліну як інгібітори реплікації вірусів денге
CO2021003391A2 (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6
MX2023010303A (es) Metodo de modulacion de las vias de se?alizacion de tigit y pd-1 mediante el uso de compuestos de 1,2,4-oxadiazol.
MX2021000841A (es) Derivados de quinazolinona sustituidos y su uso como moduladores alostericos positivos de mglur4.
WO2023178111A3 (en) Organic compounds
MA41633B1 (fr) Composés amide en tant qu'agonistes du récepteur 5-ht4
CR20200355A (es) Compuestos para el tratamiento de trastornos dependientes de cinasas
JP2018530608A5 (cg-RX-API-DMAC7.html)
MX2025007656A (es) Gamma-carbolinas heterociclicas fusionadas que actuan en el receptor de serotonina 5-ht2a
JP6877359B2 (ja) イミダゾール誘導体